NORTH CHICAGO, IL and ROCKVILLE, MD, USA I January 13, 2025 I AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ...
SHANGHAI, China and NORTH CHICAGO, IL, USA I January 13, 2025 I Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc.
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ...
SHANGHAI, China I January 13, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
TEL AVIV, Israel I January 13, 2025 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) ...
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I January 12, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...
PLYMOUTH, MA, USA I January 13, 2025 I GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK ...
NEW HAVEN, CT, USA and UTRECHT, The Netherlands and CAMBRIDGE, MA, US AI January 12, 2025 I Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), ...
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...
INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...
UTRECHT, The Netherlands and PHILADELPHIA, PA, USA I January 10, 2025 I LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback